Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2
Conditions
Interventions
- BIOLOGICAL: onasemnogene abeparvovec-xioi
Sponsor
Novartis Gene Therapies
Collaborators